ArticleeLife2020
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers.
0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 195 citations in OpenAlex.
- SIRT5-Mediated Desuccinylation of ACAA2 Protects Against Calcium Oxalate-Induced Kidney Injury by Regulating Fatty Acid Oxidation to Suppress Mitochondrial Oxidative Injury and Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ferroptosis and prostate cancer: A translational path from molecular mechanisms to precision therapy.Genes & diseases · 2026Review
- Plasma mitochondrial-associated proteins scale with illness severity and predict outcome in suspected sepsis.Critical care (London, England) · 2026Article
- GIPC1 governed ferroptosis by regulating DECR1-modulating lipid homeostasis during dilated cardiomyopathy (DCM).Cell death and differentiation · 2026Article
- Intermediate accumulated upon interruption of fatty acid oxidation flux promotes tumoral ferroptosis and improves immunotherapy.Nature communications · 2026Article
- USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer.Cell death & disease · 2026Article
- Article
- Targeted proteomic analyses during combined angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist administration (CARDALIS®) in healthy dogs.Journal of veterinary internal medicine · 2026Article
- Ferroptosis in Neuropsychiatric and Neurodegenerative Disorders: Shared Mechanisms and Disease-Specific Signatures.Pharmaceuticals (Basel, Switzerland) · 2026Review
- ACAA1 mediates arachidonic acid dysregulation and membrane phospholipid remodeling to promote crystal-cell adhesion and ferroptosis susceptibility in calcium oxalate kidney stone.Journal of pharmaceutical analysis · 2026Article
- Targeting ferroptosis in cancer: from mechanistic insights to therapeutic approaches.Molecular biomedicine · 2026Review
- Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies.Prostate cancer and prostatic diseases · 2026Review
- Hyperandrogenemia Induces Trophoblast Ferroptosis and Early Pregnancy Loss in Patients With PCOS via CMA-Dependent FTH1 Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Regulation of apoptosis, ferroptosis, and pyroptosis mediated by acetylation.Cell death discovery · 2026Review
- Androgen receptor signaling organizes ferroptosis escape in castration-resistant prostate cancer: a threshold-based model for therapeutic timing.Frontiers in oncology · 2026Review
- Mitochondrial convergence of ferroptosis and cuproptosis in castration-resistant prostate cancer: From metabolic vulnerabilities to therapeutic targeting.BBA advances · 2026Review
- Article
- Deciphering the Iron Metabolism and Ferroptosis in Diabetic Wound Healing.Current diabetes reviews · 2026Review
- Integrative transcriptomic and single-cell analysis reveals mitochondrial-related gene biomarkers in heart failure with preserved ejection fraction.Scientific reports · 2025Article
- The essential role of 2,4-dienoyl-CoA reductase for the degradation of complex fatty acid mixtures.mBio · 2025Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 2 countries.
Zeyad D Nassar *University of Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-7779-2697
Chui Yan Mah *University of Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-8820-4037
Jonas DehairsKU Leuven- University of Leuven, LKI- Leuven Cancer Institute, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium.
Ingrid Jg BurvenichTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Swati IraniUniversity of Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia.
Margaret M CenteneraUniversity of Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia.
Madison HelmUniversity of Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia.
Raj K ShresthaDame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, Australia.
Max MoldovanSouth Australian Health and Medical Research Institute, Adelaide, Australia.
Anthony S DonNHMRC Clinical Trials Centre, and Centenary Institute, The University of Sydney, Camperdown, Australia.
Jeff HolstTranslational Cancer Metabolism Laboratory, School of Medical Sciences and Prince of Wales Clinical School, UNSW Sydney, Sydney, Australia.
Andrew M ScottTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Lisa G HorvathGarvan Institute of Medical Research, NSW 2010; University of Sydney, NSW 2006; and University of New South Wales, Darlinghurst, Australia.
David J LynnSouth Australian Health and Medical Research Institute, Adelaide, Australia.
Luke A SelthUniversity of Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia.
Andrew J HoyDiscipline of Physiology, School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Johannes V SwinnenKU Leuven- University of Leuven, LKI- Leuven Cancer Institute, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium.
Lisa M ButlerUniversity of Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia.ORCID 0000-0003-2698-3220
South Australian Health and Medical Research Institute · AUThe University of Sydney · AUFlinders University · AUKU Leuven · BELa Trobe University · AUThe University of Adelaide · AUUNSW Sydney · AU
Funding
Australian Research Council FT130101004Australian Research Council Future Fellowship,FT130101004Cancer Council South Australia Beat Cancer Fellowship,PRF1117Cancer Council South Australia PRF1117Cure Cancer Australia Foundation 1164798Cure Cancer Australia Foundation Project Grant,1164798EMBL Australia Group Leader AwardFonds Wetenschappelijk Onderzoek Project Grants G.0841.15 and G.0C22.19NKU Leuven Project Grants C16/15/073 and C32/17/052Movember Foundation MRTA3Movember Foundation Revolutionary Team Award,MRTA3National Health and Medical Research Council 1084178National Health and Medical Research Council 1100626National Health and Medical Research Council 1121057National Health and Medical Research Council 1138648National Health and Medical Research Council Early Career Fellowship,1138648National Health and Medical Research Council Fellowship,1084178National Health and Medical Research Council Project Grant,1100626National Health and Medical Research Council Project Grant,1121057Prostate Cancer Foundation of Australia YI 1417Prostate Cancer Foundation of Australia Young Investigator Award,YI 1417University of Sydney Robinson Fellowship
Abstract
Fatty acid β-oxidation (FAO) is the main bioenergetic pathway in human prostate cancer (PCa) and a promising novel therapeutic vulnerability. Here we demonstrate therapeutic efficacy of targeting FAO in clinical prostate tumors cultured ex vivo, and identify
Indexed as
FerroptosisCell Line, TumorFatty Acids, UnsaturatedHumansMaleOxidation-ReductionOxidoreductases Acting on CH-CH Group DonorsProstatic Neoplasms2,4-dienoyl-CoA reductaseFatty Acids, UnsaturatedOxidoreductases Acting on CH-CH Group Donorsandrogencancer biologyferroptosishumanlipid metabolismmouseprostate cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.